



**PSI** 

**CONTRACT DRUG DEVELOPMENT COMPANY**

November 2008

## **PSI ACES FDA INSPECTIONS**

Over the past month, PSI-managed trial sites have successfully undergone two FDA inspections following completion of a pivotal phase III registration program in prostate cancer. No findings were made in either of the two inspections.

Overall, PSI-managed studies have been through twenty-four audits by the FDA.

PSI is a full-service CRO operating globally with special focus on high enrolling countries of Eastern Europe and Latin America. PSI is known and respected for consistently securing fast patient enrollment into clinical studies of all sizes and levels of complexity, across a broad range of indications.

For more information about PSI visit [www.psi-cro.com](http://www.psi-cro.com) or contact Ginny Payeur at +1 (650) 592 9101 or [ginny.payeur@psi-cro.com](mailto:ginny.payeur@psi-cro.com)

